As part of the Company’s new commercial strategy, in November 2012 the Company implemented a strategic reorganization in its research and development department, away from its previous focus on early
stage discovery and toward a more commercially-oriented role in support of studies designed to further differentiate and support the BGM Galectin-3 and CardioSCORE tests in the marketplace. As a result of this strategic reorganization, 11 positions
in early discovery research have been eliminated, enabling the Company to dedicate a greater share of its research and development budget to commercial support and market growth activities. As a result, the Company will record a fourth quarter
charge of approximately $150,000, with expected savings of up to $1.2 million in 2013. After this strategic reorganization, the Company will have 26 full time employees.